加味寿胎颗粒联合干扰素治疗慢性乙型肝炎疗效观察

目的观察加味寿胎颗粒联合α-2b干扰素治疗慢性乙型肝炎的临床疗效。方法 60例e抗原阳性的慢性乙肝患者随机分为治疗组和对照组各30例,对照组单用α-2b干扰素(安福隆)500万u,皮下注射,隔日1次;治疗组采用干扰素注射联合加味寿胎颗粒冲服,10 g/次,3次/d,疗程6个月。结果治疗组e抗原阴转率60%,HBV-DNA转阴率为76.7%;对照组e抗原阴转率33.3%,HBV-DNA转阴率为43.3%,两组比较,差异有统计学意义(P<0.05)。结论α-2b干扰素联合加味寿胎颗粒可以显著提高e抗原阳性的慢性乙型肝炎的治疗效果。     

抗生素电子仿生信息仪直流电导入加按摩治疗慢性前列腺炎

目的：观察抗生素电子仿生信息仪直流电导入治疗慢性前列腺炎的疗效。方法：对确诊的１４３例患者随机分为：（１）实验组：７６例用抗生素电子仿生信息仪的直流电导入加按摩疗法治疗；（２）对照组：６７例用抗生素口服或注射加按摩疗法治疗；治疗１～３个疗程结束试验统计疗效。结果：实验组和对照组的治愈率分别为６５．８％、４４．８％；总有效率分别为９３．４％、６５．７％（Ｐ分别＜０．０５，０．０１）。结论：抗生素电子仿生信息仪直流电导入加按摩疗法治疗慢性前列腺炎的疗效好，无任何副作用和不适，操作简便，经济和易为患者所接受     

Qualitative Risk Assessment of Chronic Renal Failure Development in Healthy,Female Cats as Based on the Content of Eicosapentaenoic Acid in Adipose Tissue and That of Arachidonic Acid in Plasma Cholesteryl Esters

A study was carried out to assess the qualitative risk of development of chronic renal failure (CRF) in young healthy, female cats as based on the content of arachidonic acid (AA) in plasma cholesteryl esters (CE) and eicosapentaenoic acid (EPA) in adipose tissue. It has been suggested that the content of AA in CE should be <10% of total fatty acids (TFA) and of EPA in adipose tissue be >1.4% of TFA. Subcutaneous adipose tissue and blood samples were obtained from 48 female cats. There was a statistically significant correlation between linoleic acid content of adipose tissue and that of plasma CE. In all cats the EPA content of adipose tissue was lower than 1.4% of TFA and in 30 cats that of AA in plasma CE was higher than 10% of TFA. The EPA content of adipose tissue and the AA content of plasma CE are determined by the contents of these fatty acids in the diet. It is concluded that the fatty acid composition of cat foods should be determined and that, if deemed necessary, the ingredient composition should be altered so that the content of EPA is raised and that of AA is lowererd.     

Acute megakaryoblastic leukemia with erythrophagocytosis and thrombosis in a dog

A 7-year-old, intact male Dachshund was presented to the Lyon veterinary school for lethargy and anorexia of several weeks duration. The main clinical signs were pale and icteric mucous membranes, hepatomegaly, splenomegaly, and lymphadenopathy. Results of a CBC and plasma biochemistry tests revealed severe nonregenerative anemia, thrombocytopenia, and increased alanine aminotransferase and alkaline phosphatase activities. Blood smear evaluation and cytologic examination of lymph node and bone marrow aspirate specimens revealed a large population of poorly differentiated blast cells with morphologic features suggesting megakaryocytic lineage. A low number of well-differentiated but dysplastic megakaryocytes also were observed in lymph node and bone marrow smears. A few blast cells were erythrophagocytic. Blast cells were positive for glycoprotein IIIa, factor VIII-related antigen, and factor XIII using immunocytochemistry. The dog was euthanized and necropsied. Histologic findings consisted of diffuse, massive infiltration of lymph nodes, liver, and spleen by megakaryoblasts and atypical megakaryocytes, with widespread thrombosis. This case confirms the usefulness of immunochemistry, including for factor XIII, in the diagnosis of megakaryoblastic leukemia, and demonstrates the unique features of tumor cell erythrophagocytosis and marked fibrinous thrombosis, which have not been reported previously in dogs.     

Multiple myeloma in 16 cats: a retrospective study

BACKGROUND: There is limited published information regarding feline multiple myeloma. Diagnostic criteria are derived from canine studies and to our knowledge, have not been critically reviewed for cats. OBJECTIVE: To evaluate the clinical and laboratory findings in cats with multiple myeloma and appraise diagnostic criteria. METHODS: Retrospective evaluation of medical records was performed. Inclusion required an antemortem diagnosis of multiple myeloma using 2 of 4 criteria: 1) >or=20% plasma cells in the bone marrow, or >or=10% if atypical plasma cells; 2) paraproteinemia; 3) radiographically-evident osteolysis; 4) light chain proteinuria. Alternatively, a postmortem diagnosis was based on the findings of multiple plasma cell neoplasms, with marrow involvement. RESULTS: Sixteen cats were diagnosed with multiple myeloma between 1996 and 2004, with a median age of 14.0 years; 9 of 16 (56%) were castrated males, and 7 of 16 (44%) were spayed females. Laboratory abnormalities included hyperglobulinemia (14/16, 87.5%), with 11/14 (78.5%) monoclonal and 3/14 (21.4%) biclonal gammopathies; hypoalbuminemia (4/16, 25%); light chain proteinuria, (4/9, 44.4%); hypocholesterolemia (11/16, 68.7%); hypercalcemia, (3/15, 20%); nonregenerative anemia, (11/16, 68.7%); regenerative anemia, (1/16, 6.2%); neutropenia (5/15, 33.3%); thrombocytopenia (8/16, 50%); and marrow plasmacytosis (14/15, 93.3%). Plasma cells were markedly immature, atypical, or both in 10 of 12 (83.3%) cats. Focal or multifocal osteolysis was noted in 6 of 12 (50%) cats for which radiographs were available for review; generalized osteopenia was found in 1 (8.3%) cat. Noncutaneous, extramedullary tumors were found in all cats assessed, 7/7 (100%), including spleen (6), liver (3), and lymph nodes (4). The disease in 1 of 2 cats with cutaneous tumors progressed to plasmacytic leukemia. CONCLUSIONS: Common findings in feline multiple myeloma include atypical plasma cell morphology, hypocholesterolemia, anemia, bone lesions, and multi-organ involvement. Based on the results of this study, we advocate modifying diagnostic criteria in cats to include consideration of plasma cell morphology and visceral organ infiltration.     

Classification of myeloid neoplasms: a comparative review

Classification of myeloid neoplasms in veterinary medicine was modeled in the early 1990s after French-American-British and National Cancer Institute systems used in human medicine. Recently our physician counterparts, in collaboration with oncologists, constructed a new World Health Organization (WHO) standard. WHO revisions lower the blast threshold from 30% to 20% for diagnosing acute myeloid leukemia (AML) and expand and redefine AML categories. AML is now subdivided into 4 broad groups: 1) AML with recurrent genetic abnormalities, 2) AML with multilineage dysplasia, 3) AML with previous chemotherapy and/or radiation, and 4) AML, not otherwise categorized. AML alphanumeric designations (M1, M2, etc) have been discontinued as numbers of subtypes have increased. The lower blast percentage eliminates one category of myelodysplastic syndrome (MDS): refractory anemia with excess blasts in transformation. A new MDS category was created: refractory cytopenia with multilineage dysplasia (RCMD), with lineage dysplasia assessed using newly defined percentage limits. At least 10% of cells from each of 2 lineages must display atypia for a diagnosis of RCMD. That threshold is 50% for diagnosing AML with multilineage dysplasia. Chronic myelomonocytic leukemia has been removed from the MDS category and included in a new category of diseases that have features of both MDS and chronic leukemia. WHO revisions are a signal to veterinary clinical pathologists to assess the validity of our system, which was built on premises now questioned.     

Multilobulated "flower" cells in a subcutaneous mass aspirate from a cat

An 8-year-old intact male cat was presented with a subcutaneous mass in the region of the right jugular vein. Cytologic and histopathologic examinations revealed cells with multilobulated nuclei (flower cells). Immunochemistry using a panel of markers showed vimentin-positivity on cytologic specimens, and postive staining for CD79a and BLA36 on histologic specimens. The final diagnosis was lymphoma of B-cell origin. We have observed similar multilobulated cells in ascites fluid, thoracic fluid, and peripheral blood from dogs and cats with a variety of lymphoid and myeloid neoplasms. Cells with multilobulated nuclei that resemble flower petals also have been described in humans. These cells are infrequently observed in canine and feline cytology specimens and require immunochemistry to determine their cell of origin.     

The inducement,restricted usage and clonal expansion of TCR Vβ subfamily T cells related to chronic myelogenous leukemia

AIM: To investigate the anti-leukemia effect, the restricted usage and clonal expansion of TCR Vβ subfamily T cells from donor peripheral blood induced by chronic myelogenous leukemia(CML) cells, K562 cells and bcr-abl peptide, respectively. METHODS: T cells in donor's peripheral blood were stimulated with CML cells, K562 cells and bcr3-abl2 peptide and amplified by MLTC, to induce the CML specific cytotoxic T lymphocytes. The induced T cells were further analyzed for the restricted usage and clonal expansion of TCR Vβ subfamilies by using RT-PCR and genescan analysis, and the detection of specific cytotoxicity in CML by LDH release assay. RESULTS: 10-13 Vβ subfamilies were expressed in T cells from donor peripheral blood which were induced with CML cells, K562 cells and bcr-abl peptide in 1-2 weeks by MLTC. Oligoclonal T cell in Vβ16, Vβ21 and oligoclonal tendency T cells in Vβ5, Vβ13 subfamilies were identified in induced T cells, which have the ability of specific cytoxicity to CML cells and K562 cells. CONCLUSION: The anti-CML cytotocity T cells were induced by CML cells, K562 cells and bcr-abl peptide. These induced T cells with specific cytoxicity effect may come from the clonal expansion TCR Vβ subfamily T cells.